Article Contents ::

Details About Generic Salt ::  Pramipex

Main Medicine Class:: Antiparkinson,Non-ergot dopamine receptor agonist   

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

 

Drugs Class ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Indications for Drugs ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Dose ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Contraindication ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Precautions ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Side Effects ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Mode of Action ::  

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Interactions ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Drug Assesment ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Storage/Management ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Drug Notes ::

(pram-ih-PEX-ole)
Mirapex
Class: Antiparkinson/Non-ergot dopamine receptor agonist

 

Action Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms.

 

Indications Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used in conjunction with L-dopa.

 

Contraindications Standard considerations.

 

Route/Dosage

Individualize by careful titration. ADULTS: PO Initial dose: 0.125 mg tid. Maintenance dose: Dosage may be increased every 5 to 7 days to maximum dose of 4.5 mg/day.

 

Interactions

Drugs eliminated via cationic renal secretion (eg, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine): May reduce oral clearance of pramipexole. Pramipexole dosage adjustment may be needed if therapy with any of these agents is started or stopped during treatment with pramipexole. Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes): May reduce effectiveness of pramipexole.

 

Lab Test Interferences None well documented.

 

Adverse Reactions

CV: Orthostatic hypotension. CNS: Dizziness; somnolence; headache; confusion; hallucinations; abnormal dreams; tremor; insomnia; aggravated Parkinson’s disease; dyskinesia; hypokinesia; hypesthesia; amnesia; extrapyramidal syndrome; abnormal thinking; hypertonia; akathisia; dystonia; delusions; paranoid reactions. EENT: Abnormal vision; rhinitis. GI: Nausea; dyspepsia; constipation; dry mouth; anorexia; dysphagia. GU: Urinary tract infection; urinary frequency; urinary incontinence; impotence; decreased libido. RESP: Dyspnea; pneumonia. OTHER: Asthenia; edema; malaise; injury; fever; weight decrease; myoclonus.

 

Precautions

Pregnancy: Category C. Lactation: Inhibits prolactin secretion. Do not give to nursing mothers. Children: Safety and efficacy have not been established. Elderly: Incidence of hallucinations appears to be increased with age. Renal function impairment: Use with caution in presence of moderate-to-severe renal function impairment. Use lower initial and maintenance doses. Hypotension: Postural hypotension may occur, especially during dose escalation. Hallucinations: Can occur during pramipexole therapy. Frequency is greater when used in conjunction with L-dopa. Dyskinesia: Pramipexole may potentiate dopaminergic side effects of L-dopa and may cause or exacerbate pre-existing dyskinesias. Abrupt withdrawal: Rapid withdrawal or dose reduction of antiparkinsonism drugs may produce symptoms resembling the neuroleptic malignant syndrome. Retinal pathology: Pathological changes were observed in the retinas of albino rats receiving dopaminergic receptor agonists. The potential significance of this effect in humans has not been established but cannot be disregarded. CNS effects: Use concomitant CNS depressants with caution because of additive sedative effects. Concurrent L-dopa use: When pramipexole is used in combination with levodopa, the dose of levodopa may be reduced as tolerated.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer tid without regard to food.
  • If nausea occurs, administer each dose with food.
  • Store at controlled room temperature protected from light.

 

Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Note renal function impairment.
  • Complete baseline assessment of parkinsonian symptoms before instituting therapy.
  • Assess for therapeutic effects, adverse reactions, and drug interactions throughout course of therapy.
  • Assess for orthostatic hypotension, dizziness, and mental status changes during initial phase of therapy or following dose escalation.
  • Assist patient with position changes and ambulation during initial therapy to prevent falling.
  • Monitor blood pressure and pulse routinely during therapy.
  • Do not administer if significant changes in BP, pulse, or mental status occur. Notify physician.

 

Patient/Family Education

  • Instruct patient to take exactly as prescribed. Advise patient that dose may be taken without regard to meals but to take with food if nausea occurs.
  • Inform patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
  • Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report the following symptoms to physician: Uncontrollable movements, dizziness, mood or mental changes, severe or persistent nausea, headache.
  • Inform patient that hallucinations can occur and that elderly are more susceptible.
  • Advise patient to use caution when taking other drugs with CNS depressant effects (eg, alcohol, sedatives).
  • Advise patient not to take any other medications (including otc) without consulting physician.
  • Advise patient to notify physician if becoming pregnant, planning to become pregnant, or are breastfeeding while taking this medication.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.